Good vs Bad Cholesterol and the Cholesterol Myth

Introduction

For decades, cholesterol has been framed as a central culprit in cardiovascular disease (CVD), leading to widespread recommendations for low-fat diets and aggressive statin therapy. This view, however, has come under increasing scrutiny. While cholesterol is essential for life, the distinctions between “good” and “bad” cholesterol—namely, high-density lipoprotein (HDL) and low-density lipoprotein (LDL)—have been oversimplified. Moreover, the so-called “cholesterol myth”—the belief that dietary and total serum cholesterol are primary causes of heart disease—is increasingly being challenged by contemporary research. This paper critically examines the roles of HDL and LDL cholesterol, evaluates the scientific support behind traditional cholesterol theory, and explores more accurate predictors of cardiovascular risk.

The Biological Role of Cholesterol

Cholesterol is a lipid molecule vital for numerous physiological functions. It serves as a precursor to steroid hormones, bile acids, and vitamin D, and is a fundamental component of cell membranes (Dietschy, 2009). The human body synthesizes about 1,000 mg of cholesterol daily, with the liver playing a significant role in this endogenous production. Thus, dietary cholesterol exerts a relatively minor influence on overall serum levels due to homeostatic regulation (Fernandez & Webb, 2008).

Understanding LDL and HDL: Function and Misconceptions

LDL is commonly labeled “bad” cholesterol because elevated LDL levels have been associated with atherosclerosis, the buildup of fatty plaques in arteries. However, not all LDL is inherently harmful. LDL particles vary in size and density, with small, dense LDL (sdLDL) more likely to penetrate arterial walls and undergo oxidation, triggering an inflammatory response (Austin et al., 1990). In contrast, large, buoyant LDL is considered less atherogenic.

Conversely, HDL is considered “good” cholesterol due to its role in reverse cholesterol transport—removing cholesterol from peripheral tissues and returning it to the liver for excretion. Higher HDL levels are inversely associated with CVD risk. However, very high HDL levels may not be uniformly protective and can sometimes correlate with increased risk due to dysfunctional HDL particles (Rohatgi et al., 2014).

Revisiting the Cholesterol Myth

The “cholesterol myth” posits that elevated serum cholesterol, particularly LDL, directly causes heart disease and that lowering it will proportionately reduce cardiovascular events. This theory has informed public policy and clinical practice for decades. However, extensive observational studies and meta-analyses have called into question its validity.

A systematic review by Ravnskov et al. (2016) examined 19 studies involving over 68,000 elderly individuals and found either no association or an inverse association between LDL cholesterol and all-cause mortality. Similarly, the Framingham Heart Study, often cited to support cholesterol theory, found that after age 50, total cholesterol was not a predictive factor for CVD mortality (Anderson et al., 1987).

Further complicating the narrative, approximately 50% of individuals hospitalized for myocardial infarction have normal or low LDL levels (Sachdeva et al., 2009). These findings suggest that LDL alone is an insufficient marker for cardiovascular risk.

Dietary Cholesterol: No Longer a Villain

Previously, dietary cholesterol was thought to increase blood cholesterol levels and contribute to the development of heart disease. As a result, eggs and other cholesterol-rich foods were discouraged. However, research has consistently shown that dietary cholesterol has minimal impact on serum cholesterol for most individuals.

The 2015–2020 U.S. Dietary Guidelines removed the previous 300 mg/day cap on cholesterol intake, citing a lack of evidence that dietary cholesterol significantly affects serum cholesterol or CVD risk (U.S. Department of Health and Human Services & USDA, 2015). A meta-analysis by Berger et al. (2015) found no relationship between egg consumption and the incidence of coronary heart disease or stroke in healthy populations.

Statins and the Pharmaceutical Influence

Statins are widely prescribed to lower LDL cholesterol and have demonstrated benefits in high-risk populations, particularly those with existing cardiovascular disease. However, their utility in primary prevention remains a topic of debate. While statins modestly reduce LDL levels and CVD events, their effectiveness appears overstated in low-risk groups, especially when side effects and quality-of-life impacts are considered (Diamond & Ravnskov, 2015).

Furthermore, concerns about industry bias in statin trials and the use of surrogate markers, such as LDL-C, rather than hard outcomes, like all-cause mortality, warrant caution. The focus on LDL reduction may detract from addressing more significant drivers of CVD, such as inflammation and insulin resistance.

Better Predictors of Cardiovascular Risk

Newer approaches to cardiovascular risk assessment emphasize inflammatory markers, metabolic health, and particle-based metrics. Apolipoprotein B (ApoB), which reflects the number of atherogenic lipoproteins, is considered superior to LDL-C in predicting heart disease (Sniderman et al., 2003). Additionally, the triglyceride-to-HDL ratio is a strong predictor of insulin resistance and cardiovascular events, especially in populations with metabolic syndrome (da Luz et al., 2008).

Moreover, high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) [Lp(a)] levels provide insight into underlying inflammation and genetic predispositions that are not captured by traditional cholesterol panels.

The Role of Inflammation and Insulin Resistance

CVD is increasingly recognized as a chronic inflammatory disease, with oxidative stress, endothelial dysfunction, and insulin resistance playing pivotal roles (Libby et al., 2011). Elevated blood glucose, hyperinsulinemia, and obesity can contribute to the formation of vulnerable plaques even in individuals with normal cholesterol levels. This shift from a lipid-centric model to one focused on systemic inflammation and metabolic health represents a paradigm change in preventive cardiology.

Conclusion

The traditional view that dietary and total serum cholesterol play a central role in heart disease has been increasingly challenged by modern research. While HDL and LDL remain relevant, focusing solely on these markers oversimplifies the assessment ofcardiovascular risk. Particle size, inflammatory status, insulin sensitivity, and lifestyle factors provide a more comprehensive understanding of heart health. Clinical strategies must evolve beyond lowering LDL to promoting metabolic health through personalized nutrition, exercise, and targeted biomarkers. Reassessing the cholesterol myth is not only scientifically justified but essential for effective cardiovascular prevention in the 21st century.

References

Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA, 257(16), 2176–2180. https://doi.org/10.1001/jama.1987.03390160062027

Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990). Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation, 82(2), 495–506. https://doi.org/10.1161/01.CIR.82.2.495

Berger, S., Raman, G., Vishwanathan, R., Jacques, P. F., & Johnson, E. J. (2015). Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. The American Journal of Clinical Nutrition, 102(2), 276–294. https://doi.org/10.3945/ajcn.114.100305

da Luz, P. L., Favarato, D., Faria-Neto, J. R., Lemos, P., & Chagas, A. C. (2008). High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics, 63(4), 427–432. https://doi.org/10.1590/S1807-59322008000400003

Diamond, D. M., & Ravnskov, U. (2015). How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Review of Clinical Pharmacology, 8(2), 201–210. https://doi.org/10.1586/17512433.2015.1012494

Fernandez, M. L., & Webb, D. (2008). The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. Journal of the American College of Nutrition, 27(1), 1–5. https://doi.org/10.1080/07315724.2008.10719668

Libby, P., Ridker, P. M., & Hansson, G. K. (2011). Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology, 54(23), 2129–2138. https://doi.org/10.1016/j.jacc.2009.09.009

Ravnskov, U., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., ... & Okuyama, H. (2016). Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open, 6(6), e010401. https://doi.org/10.1136/bmjopen-2015-010401

Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., ... & de Lemos, J. A. (2014). HDL cholesterol efflux capacity and incident cardiovascular events. New England Journal of Medicine, 371(25), 2383–2393. https://doi.org/10.1056/NEJMoa1409065

Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., & Lamarche, B. (2003). Concordance/discordance between apoB and LDL-C indicates the importance of LDL particle number in patients with the metabolic syndrome. Journal of Clinical Lipidology, 22(6), 2052–2059. https://doi.org/10.1161/01.CIR.0000099721.61965.C5

U.S. Department of Health and Human Services & U.S. Department of Agriculture. (2015). 2015–2020 Dietary Guidelines for Americans (8th ed.). https://health.gov/dietaryguidelines/2015